AADAC Polyclonal Antibody | G-AB-02165

AADAC Polyclonal Antibody | G-AB-02165 | Gentaur Antibodies

Overview: Microsomal arylacetamide deacetylase competes against the activity of cytosolic arylamine N-acetyltransferase, which catalyzes one of the initial biotransformation pathways for arylamine and heterocyclic amine carcinogens. Arylacetamide deacetylation is an important enzyme activity in the metabolic activation of arylamine substrates to ultimate carcinogens. Displays major serine hydrolase activity in liver microsomes. Hydrolyzes also flutamide, which is an antiandrogen drug used for the treatment of prostate cancer that occasionally causes severe hepatotoxicity. Displays cellular triglyceride lipase activity in liver. Increases intracellular fatty acids derived from hydrolysis of newly formed triglyceride stores.

Category Type: Polyclonal Antibody

Research Areas: Metabolism, Signal Transduction

Synonyms: AAAD, Aada, Aadac, Arylacetamide deacetylase (esterase) , Arylacetamide deacetylase, CES5A1, DAC

Reactivity: Human

Host: Rabbit

Isotype: IgG

Gene ID:

Accession #: BC032309

Clonality: Polyclonal

Immunogen: Recombinant protein of human AADAC

Clone #:

Conjugation: Unconjugated

Swissprot: P22760

Santa Cruz: sc-99249

Calculated MW: 46 kDa

Observed MW:

Concentration: 0.2 mg/mL

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification method: Affinity purification

Application: WB, IHC, ELISA

Dilution: WB 1:500-1:2000, IHC 1:25-1:100

Storage: Store at -20°C. Avoid freeze / thaw cycles.

AADAC Polyclonal Antibody DataSheet